Pivmecillinam
Brand names: Selexid
Pivmecillinam is an orally administered prodrug of mecillinam, a penicillin-class antibacterial, used principally for the treatment of acute uncomplicated lower urinary tract infection.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
After absorption it is hydrolysed to mecillinam, which binds penicillin-binding protein 2 and inhibits bacterial cell wall synthesis, with particular activity against Gram-negative organisms such as Escherichia coli.
Prescribing in practice
- It is contraindicated in patients with a history of penicillin hypersensitivity owing to the risk of cross-reactivity, including anaphylaxis.
- It should be taken with food and an adequate volume of fluid while sitting or standing upright to reduce the risk of oesophageal irritation.
- Pivmecillinam is associated with a risk of carnitine depletion and is not recommended where carnitine deficiency is a concern or for prolonged or repeated courses without specialist advice.
Monitoring
Routine laboratory monitoring is not generally required for short courses; review clinical response and reassess if symptoms fail to resolve.
Counselling the patient
- Take each dose with food and plenty of water, and do not lie down immediately afterwards.
- Complete the full course even if symptoms improve, and report any rash, swelling or difficulty breathing urgently.
Evidence & guidelines
It is recommended by NICE as a first-line option for uncomplicated urinary tract infection; consult current guidance for local antimicrobial recommendations.
Reference: NICE NG109 (UTI in adults); PHE Antimicrobial Prescribing Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- NYHA Heart Failure Classification · Heart Failure
- GRACE ACS Risk Score · Acute Coronary Syndrome
- MAGGIC Heart Failure Risk Score · Heart Failure
- WHO Functional Classification (Pulmonary Hypertension) · Pulmonary Hypertension
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- Centor/McIsaac Score (Pharyngitis) · Throat Infections